FDA Clearance Tracker · P990017
ANCURE(TM) TUBE SYSTEM, ANCURE(TM) BIFURCATED SYSTEM
Last checked: Nov 19, 2026Latest source record: Sep 28, 1999 (this decision)Source: openFDAMethods & limitations
Decided
Sep 28, 1999
Approval withdrawn
Time to decision
197 days
Received Mar 15, 1999. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class III
The decision
- FDA number
- P990017
- Device name
- ANCURE(TM) TUBE SYSTEM, ANCURE(TM) BIFURCATED SYSTEM
- Applicant
- Boston Scientific Corp
- Applicant location
- St Paul, MN
- Received
- Mar 15, 1999
- Decided
- Sep 28, 1999
- Decision
- Approval withdrawn
- Expedited review
- Yes, flagged as expedited in FDA's record.
- Supplements
- 33 in FDA's data for this PMA. See them on the FDA record
Device type
- Device class
- Class III
- Specialty
- CardiologyInterventional Cardiology
FDA's approval statement
As written in FDA's record.
Approval for the ANCURE Tube and Bifurcated Systems and the ANCURE Iliac Balloon Catheter (9 mm to 14 mm sizes). This device has the following indications for use: The ANCURE(TM) Tube System is indicated for the endovascular treatment of infrarenal abdominal aortic aneurysms (AAA) in patients having adequate iliac/femoral access, infrarenal non-aneurysmal neck length of at least 15 mm and a diameter of no greater than 26mm, distal segment neck length of 12mm and diameter of no greater than 26mm, and morphology suitable for endovascular repair. The ANCURE(TM) Bifurcated System is indicated for the endovascular treatment of infrarenal abdominal aortic or aorto-iliac aneurysms in patients having adequate iliac/femoral access, infrarenaln non-aneurysmal neck length of at least 15mm and a diameter of no greater than 26mm, distal segment lengths of at least 20mm and diameters no greater than 13.4mm, and morphology suitable for endovascular repair. The ANCURE(TM) Iliac Balloon Catheter is indicated for use in securing the attachment systems in the iliac arteries and/or to expand vascular prosthesis limbs of the ANCURE(TM) ENDOGRAFT(R) Vascular Prosthesis.
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- This is the earliest decision in FDA's data under product code MIH (SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT).
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
Other decisions for Boston Scientific Corp
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
P130030 · Decided Mar 10, 2026 · 4,453 days after receipt
Device type: STENT, CORONARY (MAF) · Cardiology
- WATCHMAN FLX Left Atrial Appendage (LAA) Closure Technology, WATCHMAN FLX Left Atrial Appendage Closure Device with DeliPMA supplement
P130013-S074 · Decided Jul 16, 2025 · 180 days after receipt · Panel Track
Device type: System, appendage closure, left atrial (NGV) · Cardiology
K243245 · Decided Oct 18, 2024 · 7 days after receipt
Device type: Unit, Cryosurgical, Accessories (GEH) · General & Plastic Surgery
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.